PRAME immunohistochemistry compared to traditional FISH testing in spitzoid neoplasms and other difficult to diagnose melanocytic neoplasms

Frontiers in Medicine

Medicine

Elizabeth Warbasse¹  Darius Mehregan²  Sarah Utz³  R. Brent Stansfield⁴  Judith Abrams⁵ 

[1]Department of Dermatology and Cutaneous Surgery, University of South Florida Morsani College of Medicine, Tampa, FL, United States

[2]Department of Dermatology, Wayne State University School of Medicine, Detroit, MI, United States

[3]Essentia Health, Duluth, MN, United States

[4]Office of Graduate Medical Education, Wayne State University School of Medicine, Detroit, MI, United States

[5]Wayne State University School of Medicine, Detroit, MI, United States

关键词: PRAME;    immunohistochemistry;    dermatopathology;    in situ;    Spitz;    melanoma;    melanocytic neoplasms;   

DOI  :  10.3389/fmed.2023.1265827

 received in 2023-07-24, accepted in 2023-09-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

PRAME (PReferentially expressed Antigen in Melanoma) is a gene first identified in melanoma. It has been proposed as a useful marker to differentiate melanoma from benign melanocytic neoplasms. Recently genomic testing using fluorescence in situ hybridization has been used to aid in the diagnosis of difficult melanocytic neoplasms. We have compared PRAME staining to FISH testing results in 83 difficult to classify melanocytic neoplasms which showed spitzoid histologic features. A relatively low sensitivity of 29.6% and high specificity of 76.8% is seen with PRAME staining as compared to genomic testing with fluorescence in situ hybridization. This study highlights the limitations of PRAME staining in spitzoid neoplasms.

【 授权许可】

Unknown   
Copyright © 2023 Warbasse, Mehregan, Utz, Stansfield and Abrams.